Navigation Links
Champions Oncology Reports Full Year 2011 Financial Results
Date:7/15/2011

eaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties.  Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements.  One should not place undue reliance on these forward-looking statements.  The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors.  See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2011 for a discussion of such risks, uncertainties and other factors.  Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations.  The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law. Champions Oncology, Inc.

Reconciliation of GAAP to Non-GAAP Net IncomeFiscal Year Ended

April  30,20112010Net loss attributable to Champions – GAAP($3,802,000)($2,923,000)Less:Stock-based compensation3,133,000593,000Net loss attributable to Champions-non-GAAP:($669,000)($2,330,000)Net income (loss) per common share attributable to Champions – GAAPBasic and diluted

Less:

Stock-based compensation per common share attributable to

Champions – non GAAP:($0.10)($0.09)Net income (loss) per common share attributable to Champions– non GAAP:  $0.08$0.02Basic and diluted($0.02)

SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing
2. Champions Biotechnology Changes Name to Champions Oncology
3. Champions Announces Technology Collaboration Utilizing Champions Tumorgraft™ Technology Platform for Oncology Drug Development
4. Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
5. Champions Biotechnology Reports Additions to its Management Team
6. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
7. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
8. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
9. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
10. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
11. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... (PRWEB) July 11, 2014 BCC Research ... DIGITAL POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS ... (PCR) technology reached nearly $140 billion in 2013. This ... registering a five-year compound annual growth rate (CAGR) of ... number of interesting and exciting possibilities within the broader ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/11/2014)... 2014 Cayenne Medical, Inc., a ... the soft tissue reconstruction segment, announced the worldwide ... surgeries involving the shoulder and extremities. The SureLock ... inserter-controlled deployment method. The unique delivery eliminates manual ... pull-out, or anchor displacement (also commonly know as ...
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... present in very low abundance and are often ... challenging and time-consuming. , Join presenters Dr. Rowel ... and Dr. John Anders, Head of Quality at ... spectrometer-based approach that can speed detection and quantitation ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2
... Powell, former,President and Chief Operating Officer of SurModics ... Corporation., Under Powell,s guidance, SurModics developed medical ... commercialize products.,Powell joined SurModics in 1987 as the ... company,s transition from a diagnostics kit,manufacturer to a ...
... July 29 SCOLR Pharma, Inc.,(Amex: DDD ) ... on Thursday, August 7, 2008, at 8:30 a.m. Eastern. ... host a conference call at 11:30,a.m. Eastern, to discuss ... participate in the,conference call by dialing +1 888 680 ...
... VOLC ), a leading manufacturer and developer ... Coherence,Tomography (OCT) products designed to enhance the diagnosis ... announced that it will,report its operating results for ... 2008 on Tuesday, August 5., The company ...
Cached Biology Technology:James C. Powell Joins Nerites Board of Directors 2SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern 2Volcano Corporation Schedules Second Quarter Conference Call, Webcast 2
(Date:7/11/2014)... Mineral Research awarded Michael F. Holick, PhD, MD, of ... Louis V. Avioli Award. Holick, a professor of medicine, ... revolutionizing the understanding of vitamin D and its role ... member of the American Society for Bone and Mineral ... basic research. It is named for ASBMR,s first president ...
(Date:7/11/2014)... 10, 2014---A team of researchers from The Chinese University ... a gene of wild soybean linked to salt tolerance, ... in saline soil. This study published online in ... novel genomic information for crop improvement. , Soybean is ... and human selection, cultivated soybeans have less genetic diversities ...
(Date:7/11/2014)... July 11, 2014 Researchers have pioneered ... images. The new technology, called Virtual Finger, allows ... structures like neurons and synapses using the flat ... technology makes 3D imaging studies orders of magnitude ... an unprecedented level across many areas of experimental ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2BGI reports a novel gene for salt tolerance found in wild soybean 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... known as a keystone species, filling such an important ... can collapse. Scientists are finding, however, that sea otters ... communities and alter the behavior of another top predator: ... towering kelp can reach heights of 250 feet and ...
... To help improve the success of oyster restoration efforts ... Environmental Science researcher Dr. Elizabeth North is leading a ... determine when oysters spawn and where their larvae go ... by a $750,000 competitive grant from the National Science ...
... DNA testing for hereditary breast cancer are associated with ... predictor of whether women had been able to leave ... the October issue of Genetics in Medicine , ... (ACMG). The journal is published by Lippincott Williams ...
Cached Biology News:Decline in Alaskan sea otters affects bald eagles' diet 2Decline in Alaskan sea otters affects bald eagles' diet 3Study looks at psychological impact of gene test for breast cancer 2Study looks at psychological impact of gene test for breast cancer 3
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
... Stain for Mass Spectrometry Applications ,In ... (MS) has emerged as a powerful protein ... 2-D gels is now an important intermediate ... leads ultimately to identification of specific proteins ...
... M-PER Mammalian Protein Extraction Reagent ... lysis solution that means no ... no sonication! With M-PER Reagent, ... five minutes at room temperature, ...
... Optimization Kits with ammonium sulfate are compatible ... such as Tfl, Tth, and Pfu DNA ... of PCR systems in one experiment by ... primers into the PreMixes supplied with the ...
Biology Products: